Sub Heading

Clinical Trials Details

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

IRB Protocol Number
EA5162

Clinical Trial Categories

  • Lung Cancer
Contact
Clinical Trials at 910-715-2200
How to Participate

Eligibility: 

Men or women, ages 18 and older, with EXON 20 mutated non-small cell lung cancer who have received prior treatment.

Contact Us

For more information on participating in a clinical trial, contact us at 910-715-2200 or talk to your doctor.